ESSAI CLINIQUE
    No essai
    ClinicalTrials.gov ID
Coordonnateur(rice)
(EN) A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    XL184-401
    NCT01896479
     Actif en recrutement
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT  

Thyroïde Johanne Guillemette
819-346-1110 poste 12880